A share price of Nektar Therapeutics [NKTR] is currently trading at $25.76, down -13.21%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The NKTR shares have gain 202.70% over the last week, with a monthly amount glided 145.58%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nektar Therapeutics [NASDAQ: NKTR] stock has seen the most recent analyst activity on June 24, 2025, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $120 from $6.50. Previously, BTIG Research reaffirmed its Buy rating on June 24, 2025, and elevated its price target to $100. On April 11, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $2 on the stock. Oppenheimer upgraded its rating to a Outperform but stick to its price target of $6 on March 14, 2025. B. Riley Securities initiated its recommendation with a Buy and recommended $4 as its price target on January 08, 2025. H.C. Wainwright started tracking with a Buy rating for this stock on December 10, 2024, and assigned it a price target of $6.50. In a note dated November 04, 2024, Piper Sandler initiated an Overweight rating and provided a target price of $7 on this stock.
Nektar Therapeutics experienced fluctuations in its stock price throughout the past year between $6.48 and $37.38. Currently, Wall Street analysts expect the stock to reach $16.75 within the next 12 months. Nektar Therapeutics [NASDAQ: NKTR] shares were valued at $25.76 at the most recent close of the market. An investor can expect a potential drop of -34.98% based on the average NKTR price forecast.
Analyzing the NKTR fundamentals
Trailing Twelve Months sales for Nektar Therapeutics [NASDAQ:NKTR] were 87.25M which represents -51.66% decline. Gross Profit Margin for this corporation currently stands at 0.75% with Operating Profit Margin at -1.31%, Pretax Profit Margin comes in at -1.48%, and Net Profit Margin reading is -1.52%. To continue investigating profitability, this company’s Return on Assets is posted at -0.52, Equity is -2.62 and Total Capital is -0.62. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of7.3.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.29 points at the first support level, and at 22.81 for the second support level. However, for the 1st resistance point, the stock is sitting at 28.25, and for the 2nd resistance point, it is at 30.73.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Nektar Therapeutics [NASDAQ:NKTR] is 3.24. Further, the Quick Ratio stands at 3.24, while the Cash Ratio is 0.55. Considering the valuation of this stock, the price to sales ratio is 3.66, the price to book ratio is 23.26.
Transactions by insiders
Recent insider trading involved Zalevsky Jonathan, Chief R&D Officer, that happened on May 19 ’25 when 10712.0 shares were sold. Chief Legal Officer, Wilson Mark Andrew completed a deal on May 19 ’25 to sell 9996.0 shares. Meanwhile, President & CEO ROBIN HOWARD W sold 23208.0 shares on May 19 ’25.
